Background and Purpose: The European Stroke Prevention Study was a multicenter trial comparing the effect of a combination of 75 mg dipyridamole and 330 mg acetylsalicylic acid three times a day with the effect of a placebo in the prevention of stroke or death in 1,861 patients after one or more episodes of recent transient ischemic attack or cerebral infarction.
D
iabetes is associated with an increased risk of atherosclerotic complications including cerebrovascular disease. The mortality from cerebrovascular disease among diabetics has been shown to be twofold to fivefold greater than among nondiabetic subjects. 1 " 3 In the Framingham Study population, the incidence of atherothrombotic brain infarction was 2.6 times higher in male diabetics and 3.8 times higher in female diabetics than in corresponding nondiabetics. 4 The reasons for an increased risk of atherosclerosis in diabetics have largely remained unsettled and are not explained by classical major risk factors (i.e., total cholesterol levels, blood pressure, or smoking). 5 All evidence suggests that the excess risk is explained by diabetes itself or factors related to it. Diabetes has multiple effects on hemostatic factors that change their internal balance in the thrombogenic direction. This may have great importance with respect to enhanced risk of cerebrovascular disease in diabetics. 5 One abnormality of the hemostatic system in diabetes is hyperreactivity of platelets. 6 -7 Whether this abnormality is influenced by platelet-inhibiting drugs is poorly known. In a cooperative study 8 in which diabetic pa-tients had limbs amputated because of gangrene, a combination of aspirin (ASA) and dipyridamole (DP) was not superior to placebo with respect to cardiovascular death. In contrast, in another study that included patients with transient ischemic attack (TIA) or brain infarction, 9 antiaggregatory drug treatment seemed to be effective in the secondary prevention of ischemic attacks in diabetic patients.
The present study represents a secondary analysis of the European Stroke Prevention Study (ESPS) concerning the effect of DP-ASA on the secondary prevention of stroke or death in diabetic and nondiabetic patients having a recent ischemic cerebral attack. The ESPS, which included 2,500 patients, demonstrated a 33% decrease in total end points (stroke or death) 10 and a 38% decrease in stroke 11 in favor of DP-ASA treatment compared with placebo.
Subjects and Methods
The aim of the ESPS was to investigate whether the combination of 75 mg DP and 330 mg ASA three times a day is more effective than placebo in the secondary prevention of stroke or death in patients with previous ischemic cerebral lesions. The ESPS was a randomized, placebo-controlled, double-blind study with parallel groups. Sixteen centers from six countries participated.
The patients included had suffered a recent (<90 days) ischemic cerebral attack (TIA, reversible ischemic neurological deficit [RIND], or stroke). TIA was defined as a neurological ischemic disorder with clinical deficits resolving fully within 24 hours, and in RIND recovery occurred within 2-7 days. A vascular event was classified as stroke if the neurological deficit persisted for >7 days.
The treatment lasted for up to 24 months, with follow-up visits every 3 months. Altogether 2,500 patients were recruited (Table 1) . Of them, 639 (26%, 324 in the DP-ASA group and 315 in the placebo group) were excluded from the explanatory analysis. Reasons for exclusion were mainly related to treatment with ASA, DP-ASA, or anticoagulant drugs before entering the trial (302 patients), too late (>90 days) inclusion (189 patients), and misdiagnosis (89 patients).
The diagnosis of diabetes was based on the World Health Organization criteria for diabetes. 12 There were 271 diabetics (168 treated with oral drugs or insulin) in the intention-to-treat analysis and 216 (128 treated with oral drugs or insulin) in the explanatory analysis. In contrast, the diabetic patients in the DP-ASA and placebo groups did not differ regarding age; smoking; systolic and diastolic blood pressure readings; medication for diabetes; history of myocardial infarction, ischemic heart disease, or cardiac failure; and the use of beta blockers or antihypertensive drugs (data not shown).
Statistical analyses were performed in two ways; the intention-to-treat analysis took into account results of all randomized patients, and the explanatory analysis was based on results from patients who were eligible and complied with the study protocol. Since the results were similar in the two statistical analyses, only the explanatory analysis is presented.
For end point analysis, survival curves were calculated by the actuarial method 13 (survival in this context means freedom from cerebral infarction or death). Survival analysis statistics for end points were calculated using the so-called D algorithm of Lee and Desu. 14 D is asymptomaticalh/ distributed as x 2 w 't R (8~1) degrees of freedom, where g equals the number of groups, under the null hypothesis that the subgroups are samples from the same survival distribution. The incidences of end points and strokes after 2 years were estimated from the survival curves. Odds ratios and their 95% confidence intervals were calculated, and their significance was evaluated using x 1 statistics.
Results
The diabetic and nondiabetic patients differed with respect to sex distribution and the frequencies of stroke, coronary artery disease, and cardiac failure ( Table 2) . Smoking was less common in the diabetics than in the nondiabetic subjects. In addition, the diabetics were older and had a higher systolic blood pressure than the nondiabetic subjects.
In both the intention-to-treat and explanatory analyses DP-ASA treatment was significantly better than placebo in total end point reduction in the nondiabetic subjects but not in the diabetic patients ( Table 3 ). The end point reduction was 22.6% in the diabetic patients and 38.8% in the nondiabetic patients. The risk of an end point evaluated on the basis of the placebo group was 1.8 (95% confidence limits, 1.1-3.0; p<0.05) times higher in the diabetic patients than in the nondiabetic patients with respect to total end points and 1.3 (95% confidence limits, 0.7-2.3; not significant) with respect to a stroke end point.
When the results were analyzed with stroke as the end point (Table 3) , the end point reduction was even greater in each group (32.4% in the diabetic patients and 47.9% in the nondiabetic patients). Although a significant difference between treatment groups was achieved only in the nondiabetic patients, there was a marked end point reduction in the diabetic patients in favor of DP-ASA treatment.
Discussion
The major finding of our study, in contrast to the French study, 9 is that the effect of antiplatelet therapy in the prevention of stroke or death was weaker in diabetic patients than in nondiabetic subjects. However, diabetic patients also had a considerable reduction in end points, but the difference between the DP-ASA and placebo groups was not significant.
One reason for the positive treatment effect in diabetics in the French study compared with ours could be differences in patients. In the French study 86% of the patients suffered from cerebral infarction at entry, while in our study the corresponding figure was only 67%. Another reason could be the low number of diabetic patients and incidence cases in both studies. In our study there were only 29 new strokes among the diabetic patients in the explanatory analysis and in the French study there were only 15 cases, which weakens the statistical power of both trials. Furthermore, the proportions of insulin-dependent and non-insulin-dependent diabetic patients might have differed.
The largest prospective study so far to evaluate the efficacy of antiplatelet drugs in diabetic patients is the Veterans Administration Cooperative Study, 10 which included 231 diabetic subjects. In that study there was no difference in major end points (atherosclerotic vascular death and amputation of the opposite extremity) among diabetic patients in the placebo and DP-ASA groups. However, diabetic patients in the DP-ASA group experienced fewer strokes and TIAs than did diabetic patients in the placebo group (p=0.02).
Although diabetic patients have an increased risk of cerebrovascular ischemic events, as shown in our study, their response to antiplatelet therapy compared with nondiabetic subjects remains unsettled. The possibly weaker therapeutic response in diabetic patients may be due to more advanced vascular disease in them since recent studies have indicated that antiplatelet agents are most effective if started early during the course of atherosclerotic vascular disease. 15 ' 16 Also, in our study the diabetic patients had more atherosclerotic vascular complications and cardiovascular risk factors than the nondiabetic subjects. Because the number of diabetic patients with end points was relatively low, it was not possible to apply multivariate analysis to investigate the role of atherosclerotic complications in modifying the effectiveness of antiplatelet therapy. Furthermore, there were more TLA patients and men in our nondiabetic group than in our diabetic group. These differences may also weaken the therapeutic effect of DP-ASA in our diabetic patients since the combination of DP and ASA seems to be more effective in reducing the risk of TLA than stroke, 17 and furthermore, antiplatelet therapy seems to be more effective in men than in 20.4 32.4% 0.149 nondiabetic patients, but antiplatelet therapy in our patient population was as effective in older age groups as in younger groups (unpublished results).
In conclusion, although the combination of DP and ASA appeared to be more effective in nondiabetic subjects than in diabetic patients in the prevention of death and stroke, this could at least in part be due to our patient population. All studies published so far, including ours, have recruited too few diabetic patients. Therefore, to prove the efficacy of antiplatelet therapy in the treatment of cerebrovascular events in diabetic patients, further follow-up studies based on more diabetic subjects are urgently needed.
